New treatments and clinical trials for drug-resistant epilepsy: interpreting the 2026 developments

A striking number in a new-treatment announcement does not answer whether that treatment fits an individual patient. The important distinctions include adult focal seizures versus a specific genetic childhood syndrome, randomized evidence versus early open observation, and an approved product versus an investigational candidate. Based on primary public information checked through September 9, 2026, this article explains selected developments and the decisions they raise for patients considering care or research in China. Wu et al.: Clinical practice guidelines for third-generation antiseizure medications, Seizure 2026;134:13–26NIH: Clinical research and trials, the basics for participants

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

An approved medicine has an authorized indication in a defined jurisdiction. An application means a developer is seeking regulatory review, while a clinical trial is designed to investigate particular questions about safety, dosing or benefit. Registration, a conference presentation or a breakthrough designation does not establish that a drug is routinely available to every patient. Nor does a planned submission establish that approval has already occurred. FDA: Breakthrough therapy designation and management, SOPP 8212 中国药物临床试验质量管理规范，2026修订全文
Neurona's April 2026 communication projected a phase 3 start in the second half of that year. After the acquisition, UCB's July 30, 2026 half-year update and current pipeline described phase 3 initiation as planned for the first half of 2027. The newer information should guide discussion, with planned initiation kept distinct from a study that has already started. UCB: Half-year update July 30, 2026, rezanecel phase 3 now planned for H1 2027 UCB current pipeline: investigational epilepsy programs
New approaches may create opportunities for suitable patients, while medication optimization, timely surgical evaluation, dietary treatment or neuromodulation remain relevant according to the epilepsy. Trial participation and ordinary specialist follow-up do not replace one another. A long wait or unsuitable eligibility criteria should not automatically suspend other worthwhile care. Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022 Wu et al.: Clinical practice guidelines for third-generation antiseizure medications, Seizure 2026;134:13–26

Quick answer

A striking number in a new-treatment announcement does not answer whether that treatment fits an individual patient. The important distinctions include adult focal seizures versus a specific genetic childhood syndrome, randomized evidence versus early open observation, and an approved product versus an investigational candidate. Based on primary public information checked through September 9, 2026, this article explains selected developments and the decisions they raise for patients considering care or research in China. Wu et al.: Clinical practice guidelines for third-generation antiseizure medications, Seizure 2026;134:13–26 NIH: Clinical research and trials, the basics for participants

Full guide

A striking number in a new-treatment announcement does not answer whether that treatment fits an individual patient. The important distinctions include adult focal seizures versus a specific genetic childhood syndrome, randomized evidence versus early open observation, and an approved product versus an investigational candidate. Based on primary public information checked through September 9, 2026, this article explains selected developments and the decisions they raise for patients considering care or research in China. Wu et al.: Clinical practice guidelines for third-generation antiseizure medications, Seizure 2026;134:13–26 NIH: Clinical research and trials, the basics for participants

Separate approval, an application and clinical development

An approved medicine has an authorized indication in a defined jurisdiction. An application means a developer is seeking regulatory review, while a clinical trial is designed to investigate particular questions about safety, dosing or benefit. Registration, a conference presentation or a breakthrough designation does not establish that a drug is routinely available to every patient. Nor does a planned submission establish that approval has already occurred. FDA: Breakthrough therapy designation and management, SOPP 8212 中国药物临床试验质量管理规范，2026修订全文

Keep the date, drug name, study identifier and population with the information you save. A candidate may have both a development code and a newer nonproprietary name. A change of name does not mean a different product, and an older projected milestone may have been superseded. These details help the clinician distinguish current information from a widely shared but outdated announcement.

Cenobamate is already part of the Chinese approval discussion

The Chinese developer's official product information states that cenobamate tablets received approval in China in 2025 for partial-onset seizures in adults with epilepsy. Continuing to describe it as simply unapproved in China would therefore be inaccurate. Its development stage differs from that of the investigational candidates below, although individual suitability and dispensing still require a specialist and pharmacy review. 翼思生物官方产品资料：西诺氨酯2025年在中国获批成人部分性发作适应证

Approval does not remove clinically important risks. Current U.S. labeling includes DRESS, QT shortening and liver-injury warnings; prescribing in China requires the applicable local instructions and a suitable monitoring plan. A newer medicine should not bypass review of allergy history, cardiac risks and interactions. Equally, waiting for a future candidate should not lead a patient to abandon necessary current treatment. DailyMed: XCOPRI U.S. prescribing information, revised August 2025, current retrieval September 2026

Azetukalner has positive phase 3 results, with regulatory work still relevant

Azetukalner, previously discussed as XEN1101, is an investigational Kv7 potassium-channel opener. In March 2026 its sponsor reported that the X-TOLE2 trial in focal-onset seizures met its primary endpoint. The reported comparison concerned changes in monthly seizure frequency over a twelve-week period. A reduction in frequency is not equivalent to the same percentage of patients becoming completely seizure-free. Xenon: Phase 3 X-TOLE2 topline results, March 9, 2026, sponsor report

The sponsor's August 6, 2026 update continued to describe a planned U.S. application in the third quarter of 2026 and ongoing studies in other seizure indications. A positive trial and an application plan are not Chinese marketing approval. They also do not establish the same result in children with a different epilepsy syndrome. Patients can discuss this development with their clinician without assuming that access is already guaranteed. Xenon: Q2 2026 development update, August 6, 2026

Long-term extension data answer a different question

A randomized comparison helps estimate differences between treatment groups under the study conditions. An open-label extension can describe longer exposure and outcomes, but continued participation, withdrawals and other treatment changes affect interpretation. When a favorable long-term result is reported, check how many participants reached that point and who is included in the analysis. The experience of those remaining may not represent every original participant. NIH: Clinical research and trials, the basics for participants Nair et al.: Nine-year prospective brain-responsive neurostimulation outcomes, Neurology 2020

Sponsor communications should also be separated into actual findings and promotional comparisons. Claims about the strongest historical result may compare different populations, periods or statistical methods. Ask which features of the research group resemble your situation and what uncertainty remains. A clinician should not convert a cross-trial marketing comparison into a personalized ranking of medicines.

Zorevunersen addresses a particular Dravet disease mechanism

Zorevunersen, also called STK-001, is an investigational antisense oligonucleotide designed to increase NaV1.1-related expression. The March 2026 NEJM publication described early open-label studies and extensions in children and adolescents with Dravet syndrome. The primary analysis addressed safety and pharmacokinetics, while clinical signals supported further development. This was not a completed positive phase 3 demonstration of disease modification for every patient. Adverse events and deaths were reported, so the findings should not be summarized as risk-free treatment. Laux et al.: Zorevunersen in children and adolescents with Dravet syndrome, NEJM March 2026

Not every epilepsy associated with an SCN1A variant has the same mechanism or fits the study requirements. Clinical diagnosis and interpretation of the variant are essential. A gene name printed in a report is not enough to determine eligibility, and another child's apparent response does not establish that the same intervention is appropriate. Genetic expertise belongs in the discussion. Krey et al.: Current practice in diagnostic genetic testing of the epilepsies, ILAE Genetics Commission, 2022 Stoke: EMPEROR and zorevunersen development status, August 3, 2026

Confirm Chinese participation through the actual EMPEROR study team

EMPEROR is the phase 3 zorevunersen study registered as NCT06872125. The sponsor's August 2026 update stated that the main U.S., UK and Japanese cohort had completed enrollment while Chinese site activation and screening were progressing. Regional cohorts and procedures differ. Completion in one region does not necessarily mean every center worldwide has closed, while activity in China does not guarantee an available place at a particular center today. ClinicalTrials.gov: EMPEROR, NCT06872125 Stoke: EMPEROR and zorevunersen development status, August 3, 2026

Use the public study information and the receiving epilepsy service to reach the appropriate research team. They must confirm current status and the relevant age, diagnosis, genetic and treatment criteria. A Chinese breakthrough designation is a development milestone, not a marketing authorization. Projected data dates can change and should not be turned into a promise of routine access by a particular month. EMPEROR sponsor study information for patients 中国药物临床试验质量管理规范，2026修订全文

Rezanecel is a defined cell-therapy program, not a generic stem-cell claim

Rezanecel, or NRTX-1001, is an investigational allogeneic GABAergic interneuron therapy studied in selected drug-resistant mesial temporal lobe epilepsy. The April 2026 sponsor report concerned small early open-label cohorts at different follow-up stages. Administration, immunosuppression-related care and long-term safety observation form part of the program. These requirements matter when assessing the burden of participation. Neurona: Open-label phase 1/2 rezanecel data, April 22, 2026; historical phase 3 timing superseded

The results cannot be generalized to an unspecified cell infusion offered elsewhere. Product identity, delivery method and clinical oversight are integral to what is being studied. Terms such as regenerative or one-time administration do not establish a permanent cure, and a study of a particular temporal-lobe population is not evidence for treating every epilepsy with cells.

The rezanecel phase 3 timetable has been updated

Neurona's April 2026 communication projected a phase 3 start in the second half of that year. After the acquisition, UCB's July 30, 2026 half-year update and current pipeline described phase 3 initiation as planned for the first half of 2027. The newer information should guide discussion, with planned initiation kept distinct from a study that has already started. UCB: Half-year update July 30, 2026, rezanecel phase 3 now planned for H1 2027 UCB current pipeline: investigational epilepsy programs

This illustrates why a travel booking or an alleged enrollment deposit should not rest on an old news story. Even a registry showing an ongoing program does not establish that a specific center is open, recruiting or able to enroll an individual. Those facts require confirmation by the research team. An investigational product does not become a freely purchasable routine service when its results are publicized.

Investigational rescue treatment has a different goal from maintenance therapy

UCB's current pipeline also includes the investigational STACCATO alprazolam drug-device combination for selected prolonged seizures. Its intended role concerns an ongoing event rather than long-term prevention of future seizures. A conventional alprazolam tablet is not interchangeable with that research delivery system, and a news report is not a reason to alter an existing emergency plan. UCB current pipeline: investigational epilepsy programs

The patient's current rescue instructions should be based on the products and training actually provided by the treating clinician. Caregivers need to know when to call emergency services, what they are authorized to administer and how to observe recovery. A future product under investigation must not distract from prompt treatment of a dangerous seizure occurring now. CDC: First Aid for Seizures

Eligibility criteria serve a specific research question

A trial may require particular ages, seizure patterns, genetic mechanisms, treatment histories or organ function. Matching the broad disease name is only a first step. Not meeting the criteria does not mean that the patient's illness is unimportant or that no other treatment is available. It may mean that the study cannot safely or reliably answer its intended question in that clinical situation. NIH: Clinical research and trials, the basics for participants EMPEROR sponsor study information for patients

Provide truthful diaries and complete medication information. Do not omit doses to reach an event threshold, alter records or stop beneficial treatment without agreement from the responsible clinician. The research team and usual care team should consider current control, participation burdens and alternative options together. A trial should fit within a clinical plan that remains workable for the patient.

Informed consent must explain what you might actually receive

Random allocation means that a participant is not guaranteed to receive the investigational treatment. Blinding or sham-controlled procedures can add further distinctions between groups. Ask what each group undergoes, whether regular therapy continues, how worsening is managed and what care is arranged after withdrawal. Phase 3 participation does not mean that everyone receives a proven effective medicine free of charge. 中国药物临床试验质量管理规范，2026修订全文 NLM: Questions to ask before joining a clinical study

Consent is an ongoing conversation, not merely a signature. Participants need understandable information, time for questions, a copy of the documents and appropriate contacts for clinical or ethical concerns. Children should receive explanations suited to their understanding alongside the involvement of their legal representative. A family's urgency should not erase the child's experience of the proposed procedures.

Clarify costs and treatment after the study ends

Investigational treatment, extra study tests, ordinary medical care, travel, accommodation and management of research-related injury may have different funding arrangements. Ask which costs the sponsor covers and which remain the participant's responsibility. The formal information for this study governs those arrangements; another participant's experience is not a reliable guide to your own costs. NLM: Questions to ask before joining a clinical study

Also ask whether continued treatment is available after completion, early withdrawal or site closure, and what the alternative would be if it is not. International participants may face repeated visits, sample collection, device care or lengthy follow-up. The practical feasibility of those later stages can matter more than the ease of attending the first appointment.

Use current Chinese research requirements

China's revised Good Clinical Practice for drug trials took effect on September 1, 2026. A Chinese study should have clear arrangements for the responsible institution, ethics review, consent and safety reporting under the applicable framework. The 2020 version should not be described as the latest, and a foreign approval or consent form is not itself authorization to conduct the same program in China. 中国药物临床试验质量管理规范，2026修订全文

Confirm research participation and the practical arrangements for an overseas patient directly with the formal medical and research services. A social-media group, an agent's promise or an isolated screenshot of a study number cannot establish these arrangements. The point of verification is to know which study is being offered, who is accountable for care and how participation would continue safely.

Keep research options within the overall treatment strategy

New approaches may create opportunities for suitable patients, while medication optimization, timely surgical evaluation, dietary treatment or neuromodulation remain relevant according to the epilepsy. Trial participation and ordinary specialist follow-up do not replace one another. A long wait or unsuitable eligibility criteria should not automatically suspend other worthwhile care. Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022 Wu et al.: Clinical practice guidelines for third-generation antiseizure medications, Seizure 2026;134:13–26

For a consultation in China, bring the relevant personal records and original links for the studies that interest you. Ask whether the research addresses your actual clinical problem, whether the evidence supports considering participation and how seizures and daily burdens will be managed while waiting. Those answers make the decision more concrete than collecting additional headlines describing a breakthrough. 中国抗癫痫协会官方网站及CAAE癫痫地图入口 NIH: Clinical research and trials, the basics for participants